Exhibit 99.1
JOINT FILING AGREEMENT
This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock, par value $0.001 per share, of Eiger BioPharmaceuticals, Inc., a Delaware corporation, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below who is named as a reporting person therein in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Date: October 20, 2023 | |||
PROPEL BIO MANAGEMENT LLC | |||
By: | /s/ Leen Kawas |
Name: | Leen Kawas | ||
Title: | Managing Member | ||
/s/ Leen Kawas | ||
Leen Kawas | ||
RICHARD AND SUZANNE KAYNE LIVING | |||
TRUST DTD 01/14/1999 | |||
By: | /s/ Richard Kayne |
Name: | Richard Kayne | ||
Title: | Trustee | ||
/s/ Richard Kayne | ||
Richard Kayne | ||
PROPEL BIO PARTNERS LLC | |||
By: | /s/ Leen Kawas |
Name: | Leen Kawas | ||
Title: | Managing Member |